Overview
Adenocarcinoma in situ (AIS) and Minimally Invasive Adenocarcinoma (MIA) represent the earliest detectable stages of lung adenocarcinoma. They fall under the umbrella of pre-invasive and minimally invasive lesions in the current World Health Organization (WHO) classification of lung tumours (2021, 5th Edition).
The distinction between these entities and invasive adenocarcinoma is critical because it dictates prognosis and treatment intensity. Both AIS and MIA are associated with a near 100% disease-specific survival rate following complete surgical resection, eliminating the need for adjuvant chemotherapy or radiation therapy.
A diagnosis of AIS or MIA is effectively a “cure” diagnosis if the lesion is completely removed with clear margins. They are not “cancer” in the aggressive, life-threatening sense, but rather the earliest precursors or forms of adenocarcinoma.
Terminology & Historical Context
Understanding older terminology helps when reviewing past medical records or literature:
| Current WHO Term (2015/2021) | Historical / Synonym Terms |
|---|---|
| Adenocarcinoma In Situ (AIS) | Bronchioloalveolar Carcinoma (BAC), Non-mucinous BAC; Clara cell adenoma (obsolete). |
| Minimally Invasive Adenocarcinoma (MIA) | Microinvasive adenocarcinoma; Minimally invasive BAC. |
| Lepidic Predominant Adenocarcinoma (LPA) | Invasive mucinous/non-mucinous BAC (mixed subtype). |
Note: The term “Bronchioloalveolar Carcinoma (BAC)” was retired in the 2011 IASLC/ATS/ERS classification because it grouped biologically distinct entities (pre-invasive, minimally invasive, and frankly invasive) under one confusing label.
Definitions & Diagnostic Criteria (Pathology)
Diagnosis is exclusively histological (microscopic examination of tissue). It cannot be definitively made on cytology (needle aspiration/brushings) or imaging alone, though imaging provides strong suspicion.
1. Adenocarcinoma In Situ (AIS)
- Size: ≤ 3 cm in greatest dimension.
- Growth Pattern: Pure lepidic growth (tumor cells grow along the surface of intact alveolar septa without destroying the underlying architecture).
- Invasion: Absent. No stromal, vascular, or pleural invasion.
- Cytology: Usually non-mucinous (Club/Clara cell or Type II pneumocyte differentiation). Mucinous AIS exists but is rare.
- Necrosis: Absent.
- Stromal Reaction: Absent (no desmoplasia/tumor-associated fibroblasts).
2. Minimally Invasive Adenocarcinoma (MIA)
- Size: ≤ 3 cm in greatest dimension.
- Growth Pattern: Predominantly lepidic (≥ 95% of the tumor area).
- Invasion: Present but limited. Invasive component measures ≤ 5 mm in greatest dimension (sum of all invasive foci if multiple).
- Invasion Patterns: Acinar, papillary, micropapillary, solid, or variant patterns (e.g., fetal, colloid).
- Exclusions: No lymphovascular invasion (LVI), no pleural invasion, no tumor necrosis, no spread through air spaces (STAS).
Pathologist’s Note: The 5 mm invasion cutoff is measured as the deepest point of invasion from the basement membrane or the largest focus** of invasive morphology. Accurate measurement requires the entire lesion to be submitted for processing (total embedding) for lesions ≤ 2 cm; representative sampling is acceptable for larger lesions but total embedding is preferred for MIA/AIS confirmation.
Radiological Features (Imaging)
High-Resolution Computed Tomography (HRCT) is the primary imaging modality. Findings correlate strongly with the lepidic growth pattern.
The “Subsolid” Nodule
Both AIS and MIA typically manifest as subsolid nodules (SSNs) – nodules containing both ground-glass opacity (GGO) and solid components.
| Feature | AIS (Typical) | MIA (Typical) | Invasive Adenocarcinoma (LPA) |
|---|---|---|---|
| Consistency | Pure Ground-Glass Opacity (pGGO) | Part-Solid (mixed GGO + Solid) | Part-Solid (larger solid component) |
| Solid Component | Absent (0 mm) | Present, ≤ 5 mm | > 5 mm |
| Size (Total) | Usually ≤ 3 cm | Usually ≤ 3 cm | Often > 3 cm |
| Borders | Well-defined, smooth, sometimes lobulated | Well-defined; solid part distinct | Irregular, spiculated, pleural tags |
| Internal | Homogeneous haziness | Solid focus within GGO | Heterogeneous, bubble-like lucencies |
| Doubling Time | Very slow (> 400–1000 days) | Slow | Faster (< 400 days) |
Key Imaging Signs
- CT Attenuation (Hounsfield Units): Pure GGOs (AIS) typically measure -200 to -600 HU. The solid component in MIA measures soft tissue density (-10 to +100 HU).
- Air Bronchograms: Frequently seen within the GGO component (patent airways trapped by lepidic cells).
- Vascular Convergence: Vessels may curve toward the lesion but do not invade it.
- Pleural Indentation/Tag: Usually absent in AIS/MIA; presence suggests invasion (LPA).
Clinical Presentation
- Asymptomatic (Majority): > 90% detected incidentally on CT scans performed for unrelated reasons (trauma, cardiac screening, abdominal pain) or lung cancer screening programs (LDCT).
- Symptomatic (Rare): Persistent cough, hemoptysis (coughing blood), or recurrent pneumonia if the lesion is central/large enough to cause bronchial obstruction (uncommon for peripheral AIS/MIA).
- Paraneoplastic Syndromes: Extremely rare (e.g., hypertrophic osteoarthropathy, SIADH).
Differential Diagnosis (What Else Could It Be?)
When a subsolid nodule is found, the radiologist and multidisciplinary team (MDT) consider:
| Category | Specific Entities | Distinguishing Features |
|---|---|---|
| Infectious / Inflammatory | Focal organizing pneumonia, Fungal infection (Aspergillosis), TB, Septic emboli | Interval change: Resolution or significant reduction on follow-up CT (4–12 weeks). “Halo sign” / “Reversed halo sign” (atoll sign). |
| Benign / Reactive | Intrapulmonary lymph nodes, Fibrosis/Scar, Lipoid pneumonia | Fat density (-40 to -100 HU) = Hamartoma/Lipoma. Stability > 2–3 years. |
| Pre-invasive | Atypical Adenomatous Hyperplasia (AAH) | Size: < 5 mm (usually < 1 cm). Pure GGO. Too small to biopsy reliably. |
| Invasive Malignancy | Lepidic Predominant Adenocarcinoma (LPA) | Solid component > 5 mm on CT or pathology. Spiculation, pleural tags, LVI. |
| Metastasis | Metastatic deposit (rarely subsolid) | Known primary cancer elsewhere; multiple nodules; “cannonball” appearance. |
Diagnostic Workup Pathway
1. Initial Detection (Incidental or Screening)
- LDCT (Low-Dose CT): Standard for screening (ages 50–80, 20 pack-year history).
- Diagnostic Chest CT with IV Contrast: Required for initial characterization if found on non-contrast scan.
2. Risk Stratification & Follow-Up (Fleischner Society / NCCN / BTS Guidelines)
Management depends on size, morphology (pure vs. part-solid), and patient risk factors.
For Pure Ground-Glass Nodules (pGGO) – Suspicious for AIS
| Nodule Size | Initial Follow-up | Long-term Management |
|---|---|---|
| < 6 mm | No routine follow-up needed (low risk) | Optional CT at 2 & 4 years (screening context). |
| 6–10 mm | CT at 6–12 months | If stable: CT every 2 years until 5 years. |
| > 10 mm | CT at 3–6 months | If persistent: PET-CT (often false negative in AIS) → Surgical Resection or Biopsy (if surgery high risk). |
For Part-Solid Nodules (PSN) – Suspicious for MIA / LPA
Focus is on the Solid Component Size.
| Solid Component Size | Management |
|---|---|
| < 6 mm (or < 100 mm³ volume) | CT at 3–6 months. If persistent/unresolved → PET-CT / Surgery. |
| ≥ 6 mm | High suspicion for invasion (MIA or LPA). Proceed to PET-CT (for staging/metabolic activity) and Surgical Resection (preferred) or Biopsy. |
Note on PET-CT: AIS and MIA frequently show low or absent FDG uptake (SUVmax < 1.5–2.0) due to low cellularity and high water content in lepidic component. A negative PET does not exclude** AIS/MIA. PET is primarily used to assess mediastinal nodes or distant mets if invasive cancer is suspected.
3. Tissue Diagnosis (When is Biopsy Needed?)
- Standard of Care: Surgical Resection is both diagnostic and therapeutic. Biopsy is not routinely recommended before surgery for resectable nodules < 3 cm with high suspicion (saves a procedure, avoids sampling error/pneumothorax).
- Indications for Pre-op Biopsy (TTNA – Transthoracic Needle Aspiration/Core Biopsy):
- Patient medically unfit for surgery (considering SBRT/Ablation).
- Suspicion of metastasis (known primary elsewhere).
- Multiple synchronous lesions (determine if primary vs. mets).
- Nodule > 3 cm (upstaging likely).
- Bronchoscopy (Navigational/Robotic): Increasingly used for peripheral nodules; diagnostic yield lower for pure GGOs (lepidic cells exfoliate poorly) vs solid nodules.
Staging
- AIS: Tis (Carcinoma in situ) → Stage 0. (TNM 8th Ed: Tis N0 M0).
- MIA: T1mi (Minimally Invasive) → Stage IA1. (TNM 8th Ed: T1mi N0 M0).
- No nodal (N) or distant (M) staging workup (mediastinoscopy, brain MRI, bone scan) is required for pure AIS/MIA confirmed by pathology, unless invasive components are found.
Treatment & Management
1. Surgical Resection (Gold Standard)
Goal: Complete removal (R0 resection) with adequate margins.
| Procedure | Indication | Lymph Node Assessment |
|---|---|---|
| Sublobar Resection (Segmentectomy preferred over Wedge) | Standard of Care for AIS & MIA ≤ 2 cm. | Systematic Nodal Sampling or Dissection recommended (N1 + relevant N2 stations) to confirm N0 status. Not required for pure AIS on frozen section, but standard for MIA/Part-solid. |
| Wedge Resection | Peripheral lesions < 1–2 cm; Poor lung function; Multiple bilateral lesions. | Not oncologic standard alone. Margins must be > tumor diameter (or ≥ 1–2 cm). Intraoperative frozen section mandatory to confirm diagnosis & margins. |
| Lobectomy | Generally NOT indicated for confirmed AIS/MIA. Reserved for: Inability to achieve margins with sublobar; Positive nodes found intraop; Invasive adenocarcinoma found on final pathology (upstaging). | Full dissection. |
Surgical Approach: VATS (Video-Assisted Thoracoscopic Surgery) or RATS (Robotic-Assisted) are standard. Open thoracotomy rarely needed.
Critical Surgical Technical Points
- Margins: Minimum > 1 cm or > Tumor Diameter for wedge. Anatomic segmentectomy provides physiologic and oncologic advantage.
- Frozen Section (Intraoperative Pathology): Essential to confirm AIS/MIA vs. Invasive Adenocarcinoma. If invasive (>5mm invasion or LVI/STAS found) → Convert to Lobectomy + Lymphadenectomy.
- Lymph Nodes: Sampling (stations 10, 11, 4R/7, 5/6) confirms true Stage 0/IA1. If nodes positive → Upstage to Stage IIIA (N2) → Adjuvant chemo indicated.
2. Non-Surgical Options (For Medically Inoperable Patients Only)
- Stereotactic Body Radiation Therapy (SBRT / SABR): High control rates (>90% at 3-5 yrs) for peripheral nodules. Dose: typically 48–50 Gy in 4–5 fractions.
- Thermal Ablation (RFA / MWA): Option for very small (< 2 cm), peripheral pure GGOs. Higher local recurrence risk than SBRT/Surgery. “Heat sink” effect less relevant in aerated lung.
- Active Surveillance: For frail patients with very slow-growing pure GGOs (<10 mm), watchful waiting with serial CT is reasonable.
Pathology Report: What to Look For (Checklist)
When you receive the final pathology report, verify these key data points:
| Parameter | AIS Standard | MIA Standard | Action if Not Met |
|---|---|---|---|
| Tumor Size (Total) | ≤ 3 cm | ≤ 3 cm | > 3 cm = T1a-c (by size) / Stage IA1-3 |
| Growth Pattern | 100% Lepidic | ≥ 95% Lepidic | < 95% Lepidic = Lepidic Predominant Adenocarcinoma (LPA) |
| Max Invasion Depth | 0 mm | ≤ 5 mm | > 5 mm = Invasive Adenocarcinoma (LPA or other) |
| Invasion Pattern | None | Lepidic + 1 invasive pattern | Micropapillary/Solid invasion = Higher risk even if <5mm (controversial, but noted). |
| Lymphovascular Invasion (LVI) | Absent | Absent | Present = Upstage to pT1a (min) / Stage IA1 + Adjuvant Chemo consideration. |
| Visceral Pleural Invasion (VPI) | Absent (PL0) | Absent (PL0) | Present (PL1/PL2) = Upstage to T2 / Stage IB. |
| STAS (Spread Through Air Spaces) | Absent | Absent | Present = Upstage risk / Consider Lobectomy/Adjuvant. |
| Margins | Negative (R0) | Negative (R0) | Positive (R1/R2) → Re-resection or Radiation. |
| Lymph Nodes Examined | N/A (Stage 0) | ≥ 3 N1 + ≥ 3 N2 stations (ideally) | pN0 confirmed. If pN+ → Stage IIIA. |
Prognosis & Survival Outcomes
| Entity | 5-Year Disease-Specific Survival (DSS) | 5-Year Overall Survival (OS) | Recurrence Rate (Local) |
|---|---|---|---|
| AIS (R0 Resection) | 100% | ~95–98% (age/comorbidity driven) | < 1% (if margins clear) |
| MIA (R0 Resection) | ~98–100% | ~90–95% | 1–3% |
| LPA (Lepidic Predominant Invasive) | ~90–95% | ~80–85% | ~5–10% |
- Cause of Death: Overwhelmingly non-cancer causes (cardiovascular, other malignancies, respiratory disease).
- Recurrence: True local recurrence of AIS/MIA is vanishingly rare. New “recurrences” are almost always new primary lung cancers (field cancerization) or metastases from an occult invasive focus missed on sampling.
Long-Term Follow-Up & Survivorship
Because patients with AIS/MIA have an excellent prognosis but a high risk of developing a second primary lung cancer (3–5% per year), lifelong surveillance is mandatory.
Recommended Surveillance Schedule (NCCN / ACCP Guidelines)
| Timeframe | Imaging Modality | Purpose |
|---|---|---|
| Post-Op (Baseline) | Chest CT with Contrast (3–6 months post-op) | Establish new baseline; check surgical bed. |
| Years 1–2 | Chest CT (Low Dose preferred) every 6 months | Detect early recurrence / new primaries. |
| Years 3–5 | Chest CT (Low Dose) Annually | Continued screening for second primaries. |
| Year 5+ | Annual Low-Dose CT Indefinitely | Lifelong lung cancer screening protocol. |
- PET-CT: Not routine for surveillance unless new suspicious nodule found.
- Brain MRI: Not indicated for AIS/MIA surveillance (risk of brain mets ~0%).
- Smoking Cessation: Single most effective intervention to reduce second primary risk.
- Comorbidity Management: Aggressive management of COPD, Cardiovascular disease (leading causes of death in this cohort).
Special Clinical Scenarios
1. Multiple Subsolid Nodules (Multifocal / Multicentric Disease)
- Synchronous Multiple GGOs: Common in adenocarcinoma spectrum.
- Management Strategy: Oligometastatic vs. Multiple Primaries.
- If histologically confirmed AIS/MIA in one nodule + other pure GGOs: Observe pure GGOs (serial CT), Resect the most suspicious/largest/part-solid nodule.
- If multiple part-solid nodules: Consider staged bilateral VATS segmentectomies or SBRT for contralateral lesions.
- Genetic Testing (EGFR/ALK/KRAS): Helpful to determine clonality (same mutation = metastatic spread; different mutations = independent primaries). Impacts staging (M1a vs multiple primaries).
2. Mucinous AIS / MIA
- Rare subtype. Columnar cells with abundant mucin (goblet cell differentiation).
- Imaging: Often larger, more consolidated, can mimic pneumonia (consolidation with air bronchograms).
- Behavior: Mucinous AIS/MIA has similar excellent prognosis if completely resected. Mucinous invasive adenocarcinoma has higher risk of multifocal spread (aerogenous spread).
3. “Upstaging” at Final Pathology
- Frequency: 15–30% of radiologically suspected AIS/MIA are upstaged to invasive adenocarcinoma (LPA or other) on final pathology.
- Reason: Sampling error (frozen section misses invasive focus) or radiologic underestimation of solid component.
- Consequence: If upstaged to invasive (>5mm invasion, LVI, VPI, STAS) → Completion Lobectomy + Completion Lymphadenectomy may be recommended (discuss in MDT).
Patient FAQs
Q: “Do I have cancer?”
A: Technically, yes—these are classified as malignant neoplasms (Tis and T1mi). However, they behave nothing like typical “cancer.” They do not spread to lymph nodes or organs. They are cured by surgery alone. Think of them as “Stage Zero” or “Pre-cancer that has just crossed the line.”
Q: “Do I need Chemotherapy or Radiation?”
A: No. There is zero role for adjuvant therapy (chemo, radiation, targeted therapy, immunotherapy) for completely resected AIS or MIA. The side effects of treatment far outweigh any theoretical benefit (which is 0%).
Q: “Why do I need CT scans forever if I’m cured?”
A: You are cured of this nodule. However, your lungs have a “field effect”—the same environmental/genetic factors that caused this nodule put you at high risk for a brand new, separate lung cancer in the future. Surveillance catches the next one early.
Q: “Can I just watch it instead of surgery?”
A: For pure GGOs < 10–15 mm, active surveillance (serial CT) is a valid, guideline-backed option, especially if you have high surgical risk. For part-solid nodules (solid part ≥ 6 mm), the risk of invasive cancer is high enough that surgery (or SBRT if inoperable) is strongly recommended.
Q: “What is a ‘Segmentectomy’ vs ‘Wedge’? Which do I need?”
A: Segmentectomy removes the anatomic lung segment (with its own artery, vein, bronchus) along with lymph nodes. It offers better margins and nodal staging. Wedge is a non-anatomic “slice.” Segmentectomy is the new standard for AIS/MIA; Wedge is reserved for poor lung function or very peripheral tiny nodules.
Glossary of Terms
- Lepidic Growth: Tumor cells spreading along the surface of intact alveolar walls (like “wallpaper”).
- Ground-Glass Opacity (GGO): Hazy increased lung attenuation on CT where vessels/bronchi are still visible.
- Consolidation / Solid Component: Opacification obscuring vessels; correlates with invasive tumor, fibrosis, or hemorrhage.
- Desmoplasia: Scarring/fibrotic reaction induced by invasive tumor cells (absent in AIS).
- STAS (Spread Through Air Spaces): Tumor cells floating in air spaces beyond the main tumor edge; adverse prognostic factor.
- Pack-Year: Packs per day × Years smoked. (e.g., 1 pack/day x 20 years = 20 pack-years).
- R0 Resection: Microscopically negative margins (no tumor at inked edge).
- Frozen Section: Rapid pathology analysis during surgery (15–20 mins) to guide surgical extent.
Resources & References (Harvard Style)
Guidelines & Classification Systems
- Travis, W.D., Brambilla, E., Burke, A.P., Marx, A. and Nicholson, A.G. (eds.) (2021) WHO Classification of Thoracic Tumours. 5th edn. Lyon: International Agency for Research on Cancer (IARC).
- Travis, W.D. et al. (2011) ‘International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma’, Journal of Thoracic Oncology, 6(2), pp. 244–285.
- National Comprehensive Cancer Network (NCCN) (2024) NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2024. Available at: https://www.nccn.org (Accessed: [Current Date]).
- MacMahon, H. et al. (2017) ‘Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017’, Radiology, 284(1), pp. 228–243.
- Goldstraw, P. et al. (2016) ‘The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer’, Journal of Thoracic Oncology, 11(1), pp. 39–51.
Key Clinical Trials & Landmark Studies (Surgery vs. Sublobar)
- Altorki, N.K. et al. (CALGB 140503 Alliance) (2023) ‘Sublobar Resection versus Lobectomy for Small Peripheral Non-Small-Cell Lung Cancer‘, New England Journal of Medicine, 388(6), pp. 489–498. (Established non-inferiority of sublobar for ≤2cm solid-dominant; highly relevant for MIA management context).
- Saji, H. et al. (JCOG0802/WJOG4607L) (2022) ‘Segmentectomy versus Lobectomy in Small-Sized Peripheral Non-Small-Cell Lung Cancer (JCOG0802): A Multicentre, Open-Label, Phase 3, Randomised, Controlled, Non-Inferiority Trial’, The Lancet, 399(10335), pp. 1607–1617. (Showed superiority of segmentectomy for OS in ≤2cm tumors).
- Lim, E. et al. (2023) ‘Video-Assisted Thoracoscopic Surgery versus Open Lobectomy for Lung Cancer (VIOLET Trial)’, BMJ, 380, p. e073158.
Pathology & Radiology Correlation
- Yanagawa, M. et al. (2019) ‘Proposal for a New Histologic Classification of Small (≤3 cm) Invasive Lung Adenocarcinoma Based on the Predominant Subtype’, Journal of Thoracic Oncology, 14(1), pp. 59–68.
- Kauczor, H.U. et al. (2020) ‘ESR/ERS White Paper on Lung Cancer Screening’, European Radiology, 30, pp. 4275–4291.
- Hasegawa, M. et al. (2020) ‘Prognosis of Resected Lung Adenocarcinoma with Lepidic Component: Impact of Tumor Size and Invasive Size’, Journal of Thoracic Oncology, 15(5), pp. 823–834.
Surveillance & Survivorship
- Van Klaveren, R.J. et al. (2021) ‘Management of Lung Nodules Detected by Low-Dose CT Screening’, Nature Reviews Clinical Oncology, 18, pp. 347–361.
- Tammemägi, M.C. et al. (2019) ‘Lung Cancer Screening: Future Directions’, American Society of Clinical Oncology Educational Book, 39, pp. 114–124.
Patient-Focused Resources
- Lung Cancer Research Foundation: Understanding Your Pathology Report: AIS & MIA (Patient Guide).
- GO2 Foundation for Lung Cancer: Lung Cancer 101: Early Stage Disease.
- American Thoracic Society (ATS) Patient Information Series: Pulmonary Nodules: What You Need to Know.